Psychiatric disorders represent a significant and growing problem for society. While many patients are effectively treated with pharmacotherapy, psychotherapy or a combination of the two, up to 30% with mood and anxiety conditions do not respond to these standard treatments (Bystritsky 2006; Rush et al. 2006). This course provides practitioners with an overview of current clinical applications for TMS therapy. The course speakers are clinician-researchers with extensive knowledge about the therapeutic applications of TMS, as well as other forms of neuromodulation. The course reviews TMS mechanism of action, applications for psychiatric conditions, patient selection for TMS, as well as a thorough review of the current FDA cleared TMS Therapy systems. Teaching techniques will include didactics, case discussion, and panel discussion.

The course begins on Monday, August 16 with a review of recorded sessions from our faculty experts. Learners will have a chance to attend live learning sessions with the faculty experts, scheduled on Wednesday, September 22 at 4:00pm ET/1:00pm PT and Wednesday, October 20 at 3:00pm ET/12:00pm PT.

Learning Objectives

• Describe the mechanism of action of TMS
• Cite the efficacy of TMS for the treatment of major depression, OCD and other psychiatric disorders
• Identify the risks and side effects of TMS
• Identify appropriate patients for TMS treatment
• Review the specifications of FDA-cleared TMS systems

Target Audience

Psychiatrists, Residents/Fellows

Estimated Time to Complete

Estimated Duration: 4 hours
Begin Date: August 16, 2021
End Date: November 1, 2021

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (other disciplines) showing the event date and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The APA designates this enduring CME activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

All financial relationships relevant to this activity have been mitigated.

Program Presenters

• Richard Bermudes, M.D., Medical Director, TMS Health Solutions; Disclosures - Speaker Honoraria for Grand Rounds for Clinical TMS Society; Royalties for Publishing: American Psychiatric Publishing Inc.
• Phillip Janicak, M.D., Director and Consultant, TMS Center, Linden Oaks Medical Group / Elin Healthcare at Edward Hospital; Disclosures - Neuronetics, Inc.; Other: Otsuka Pharmaceuticals; Other: TMS Health Solutions
• Ian Cook, M.D., Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Research Scientist, Semel Institute for Neuroscience and Human Behavior, UCLA; Disclosures - Other: Los Angeles TMS Institute, Inc., HeartCloud, Inc., BrainCloud Corp; Employee: NeuroSigma, Inc.
• Karl Lanocha, M.D., Psychiatrist; Director of TMS Education, Mindful Health Solutions; Reports no financial relationships with commercial interests.